Phase 1 dose escalation trial of intravenous radium 223 dichloride alpha-particle therapy in osteosarcoma.

Subbiah, Vivek; Rohren, Eric M.; Huh, Winston W.; Kappadath, Cheenu S; Anderson, Peter M.

doi:10.1200/jco.2014.32.15_suppl.tps10600

Cited by 5 publications

(3 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…α-particles are then released, resulting in the inhibition of bone metastases and cancer cell proliferation. Radium-223 is associated with low marrow toxicity and increased radiobiological effectiveness, particularly in bone-forming types of cancer, when compared with samarium-153-EDTMP (18,19). Radium 223 may have greater potential for widespread use against bone metastases in OS since it may achieve safe and effective decrease of tumor burden and facilitate improvements in surgery and/or radiotherapy in patients with unresectable, large or metastatic tumors.…”

Section: Samarium-153 Ethylenediaminetetramethylene Phosphonatementioning

confidence: 99%

See 1 more Smart Citation

Progress in the chemotherapeutic treatment of osteosarcoma (Review)

et al. 2018

View full text Add to dashboard Cite

Osteosarcoma (OS) is the most common type of primary bone tumor in children and adolescents and has been associated with a high degree of malignancy, early metastasis, rapid progression and poor prognosis. However, the use of adjuvant chemotherapy improves the prognosis of patients with OS. OS chemotherapy is based primarily on the use of adriamycin, cisplatin (DDP), methotrexate (MTX), ifosfamide (IFO), epirubicin (EPI) and other drugs. Previous studies have revealed that the survival rate for patients with OS appears to have plateaued: 5-year survival rates remain close to 60%, even with the use of combined chemotherapy. The most limiting factors include complications and fatal toxicity associated with chemotherapy agents, particularly high-dose MTX (HD-MTX), for which high toxicity and great individual variation in responses have been observed. Docetaxel (TXT) is a representative member of the relatively recently developed taxane class of drugs, which function to inhibit OS cell proliferation and induce apoptosis. Recently, more clinical studies have reported that TXT combined with gemcitabine (GEM) is effective in the treatment of OS (relapse/refractory and progressive), providing evidence in support of potential novel treatment strategies for this patient population. However, there is still no global consensus on this type of chemotherapy approach. The present review summarizes current studies surrounding progress in the chemotherapeutic treatment of OS and discusses the advantages and potential feasibility of TXT+GEM in the treatment of OS.

show abstract

Section: Samarium-153 Ethylenediaminetetramethylene Phosphonatementioning

confidence: 99%

“…In addition, prognosis of patients with recurrent or refractory OS is particularly poor. The function of second-line chemotherapy for recurrent OS is much less well defined and there is no accepted standard regimen (10)(11)(12)(13)(14)(15)(16)(17)(18)(19)(20). The purpose of the…”

Section: Introductionmentioning

confidence: 99%

Progress in the chemotherapeutic treatment of osteosarcoma (Review)

et al. 2018

View full text Add to dashboard Cite

show abstract

“…Antes da inclusão da quimioterapia, o tratamento dependia majoritariamente da ressecção cirúrgica, com sobrevida menor de 20% em 5 anos (Friedman, Carter, 1972;Bacci et al, 1997Marina et al, 2004. Subbiah et al, 2014;Grignani et al, 2015). Como resultado desta baixa evolução dos tratamentos nas últimas três décadas, o prognóstico é insatisfatório em pacientes com a doença metastática, recorrente ou irressecável (Miwa et al, 2019).…”

Section: Tratamento Dos Pacientes Com Osteossarcomaunclassified